about
Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive updateEffect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss dietAssociation of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia.In vitro interactions between piperaquine, dihydroartemisinin, and other conventional and novel antimalarial drugsKinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions.Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal womenLipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studiesLipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies.Lipid disorders and mutations in the APOB gene.Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetesEffects of Therapeutic Lifestyle Change diets high and low in dietary fish-derived FAs on lipoprotein metabolism in middle-aged and elderly subjects.Thematic review series: patient-oriented research. Design and analysis of lipoprotein tracer kinetics studies in humans.Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutationsFish oils, phytosterols and weight loss in the regulation of lipoprotein transport in the metabolic syndrome: lessons from stable isotope tracer studies.Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndromeMenopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women.Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.Personal model-assisted identification of NAD+ and glutathione metabolism as intervention target in NAFLD.The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia.Postprandial effects of a high salt meal on serum sodium, arterial stiffness, markers of nitric oxide production and markers of endothelial function.Recent explanatory trials of the mode of action of drug therapies on lipoprotein metabolism.Impact of commonly prescribed exercise interventions on platelet activation in physically inactive and overweight men.The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III.Modeling the Male Reproductive Endocrine Axis: Potential Role for a Delay Mechanism in the Inhibitory Action of Gonadal Steroids on GnRH Pulse Frequency.Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity.Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes.Rosuvastatin Enhances the Catabolism of LDL apoB-100 in Subjects with Combined Hyperlipidemia in a Dose Dependent Manner.Influence of simvastatin on apoB-100 secretion in non-obese subjects with mild hypercholesterolemia.Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters.The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men.Chylomicron remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test.Interrelationships between the kinetics of VLDL subspecies and HDL catabolism in abdominal obesity: a multicenter tracer kinetic study.Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
P50
Q28080477-08B5C289-D974-4840-B8FA-BFD030343BA3Q33804734-546DF3C8-9C42-4C95-9DB0-3E57D2CF404FQ34426322-E2F3589C-B8A3-4659-A67A-CC80F5B4B2F6Q34973806-E8FBD1BE-1614-4AC2-A5AE-6C77FA7990B7Q35052120-958DB5A1-028A-4F80-8A92-C25B6362D45CQ35590308-B1E0EA3D-C5A7-48F3-8D46-83C8961404BFQ35754362-25F2DC77-1BD6-4D10-B3D2-1482596307BCQ35821941-C133C220-87EE-4232-AED2-83BCAF01AB8FQ35861929-09D85A05-352D-4CC6-9373-39D5AB816193Q36055097-AD48F08F-C74C-4F2A-9A1B-AEBB590F7851Q36145257-B5766EEC-AE3D-4F2F-94FE-17699B781D4FQ36489934-860CD22B-A618-4F9F-8CAA-008CC3D49FBFQ36509548-F0ECCF88-D49B-4F6E-BF1A-4137F1E6ACC3Q36572717-D36BDC10-5242-4741-844C-65CCD2715937Q36696683-980F8179-32F1-48D4-ADB7-9AD3DB2A603EQ36807515-03573AEF-FEED-4C39-8199-D399B535AD7AQ36836003-462743D2-4596-48EE-AD40-8803A3EFCFF0Q37311103-26901FDD-261C-40A9-B254-EF205C9F8AF5Q37326019-48A22A9D-5F0B-432E-95BF-9C8975540856Q37400800-E7F31C86-1EC2-4305-B82C-C3E5FF688A7FQ37434362-5E7B1B1F-154E-425B-A914-4B65671CB524Q37727707-B3462743-2982-48EA-A67A-6F21105033B3Q38212739-16CE6F7E-DBFD-40DB-BC2B-801493D88C10Q38437995-10AF59A3-2474-4C4B-A8BB-95E65B6D2612Q38982733-039DBB50-A8EA-46C7-B51A-4EF4D04EC81CQ39231240-3560D7D8-ED1A-4E76-AEFC-38016B518253Q39374054-A15F30D4-3143-47AD-B4E8-E301F60189D5Q39631869-23D6BF7B-2974-4C26-802D-9EF64AAF2F6AQ39972616-6424DDE3-12A8-4D2F-BF00-1E7EC81BA42CQ40169408-CC408B7D-880E-4402-B8FE-969191FBB15CQ40936185-1B474B87-1AD7-416C-A912-1C45BA4653B8Q41041086-1FFF111F-7381-4C03-ABA0-3B66D61C41AEQ41160181-A1DD0B60-FFAD-4EEC-B58B-BB3AC7871BF5Q42166736-C58767D1-E535-4655-A3B9-7059AD11F80FQ42526033-88A848AB-EC88-49B2-AD68-50B53E8DEB24Q43012977-7365FB0E-5095-4355-AFAA-4B13257EFF38Q43209712-641A0478-3489-4828-ACD4-E8899A3414DCQ43687668-6793914C-A644-41D8-8A24-8736F0EDCF1FQ43718524-DF351D04-442D-47A5-9EFD-C35E20E9C6AFQ44080980-83C2CA7C-9D82-4F27-BB76-A1B027890356
P50
description
forsker
@nb
onderzoeker uit Australië
@nl
researcher ORCID ID = 0000-0003-3223-6125
@en
name
H. Barrett
@ast
H. Barrett
@nl
Phr Barrett
@en
Phr Barrett
@es
Phr Barrett
@nb
Phr Barrett
@sq
type
label
H. Barrett
@ast
H. Barrett
@nl
Phr Barrett
@en
Phr Barrett
@es
Phr Barrett
@nb
Phr Barrett
@sq
altLabel
H. Barrett
@en
prefLabel
H. Barrett
@ast
H. Barrett
@nl
Phr Barrett
@en
Phr Barrett
@es
Phr Barrett
@nb
Phr Barrett
@sq
P1153
P106
P1153
35420912900
56680191000
57189901487
57189906638
57193414699
P27
P31
P496
0000-0003-3223-6125